Verastem, Inc. (VSTM)

Oncology Corporate Profile

Stock Performance

1.9300
0.0000

HQ Location

215 First Street, Suite 440
Cambridge, MA 02142

Company Description

Verastem, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt.

Website: http://www.verastem.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
duvelisibP13K inhibitorChronic Lymphocytic Leukemia (CLL)III
defactinibP13K inhibitorChronic Lymphocytic Leukemia (CLL)II
defactinib (+ pembrolizumab)P13K inhibitorMesotheliomaIIMerck
defactinib (+ pembrolizumab)P13K inhibitorNon Small Cell Lung Cancer (NSCLC)IIMerck
duvelisibP13K inhibitorNon-Hodgkin's Lymphoma (NHL)II
defactinib (+ avelumab)P13K inhibitorOvarian cancerIIPfizer and Merck
defactinib (+ pembrolizumab)P13K inhibitorPancreatic cancerIIMerck
defactinib (+ pembrolizumab and gemcitabine)P13K inhibitorPancreatic cancerIMerck
duvelisibP13K inhibitorRefractory T-cell LymphomaI
VS-5584mTORC1/2 inhibitorLymphomaPreclinical
VS-4718 (+ abraxane)FAK/PYK2 inhibitorPancreatic cancerPreclinical
VS-4718 (+ abraxane)FAK/PYK2 inhibitorVarious cancer typesPreclinical
VS-5584mTORC1/2 inhibitorVarious cancer typesPreclinical

Pipeline image

Source


http://www.verastem.com

Recent News Headlines

Verastem Reports Year-End 2016 Financial Results

3/23/2017 08:00 pm

[Business Wire] - Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today reported financial results for the year ended December 31, 2016, and also provided an overview of certain corporate developments.

Verastem to Host Conference Call on March 23rd to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights

3/16/2017 11:00 am

[Business Wire] - Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced that the Company will host a conference call and webcast on Thursday, March 23, 2017 at 4:30 p.m.

Verastem to Present at the Oppenheimer 27th Annual Healthcare Conference

3/15/2017 08:00 pm

[Business Wire] - Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced that the company will present at the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21st at 2:10 p.m.

Verastem to Present at the 29th Annual ROTH Conference

3/7/2017 12:00 pm

[Business Wire] - Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 29th Annual ROTH Conference on Monday, March 13th at 4:00 p.m.

Verastem to Present at 19th Annual BIO CEO & Investor Conference

2/7/2017 12:00 pm

[Business Wire] - Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 19th Annual BIO CEO & Investor Conference on Tuesday, February 14th at 9:00 a.m.

Verastem Announces Dosing of First Patient in Combination Trial of Defactinib and Avelumab in Patients with Ovarian Cancer

1/26/2017 12:00 pm

[Business Wire] - Verastem, Inc., today announced dosing of the first patient in a new clinical trial evaluating avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem’s defactinib**, an investigational focal adhesion kinase inhibitor, in patients with advanced ovarian cancer.

Verastem Announces Executive Leadership Appointments and Changes

1/19/2017 09:02 pm

[Business Wire] - Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced that Hagop Youssoufian, MSc, MD, has been appointed Head of Hematology and Oncology Development.

Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan

1/9/2017 11:00 am

[GlobeNewswire] - --Appoints Four New, Highly Qualified Independent Directors: Jason Aryeh, Dr. Geoffrey Cox, Robert Forrester and Bob Oliver--–. --Announces Chairman and CEO Succession Plans--–.

Verastem Presents Phase 2 DYNAMO® Clinical Data at ASH 2016 Annual Meeting

12/6/2016 02:01 am

[Business Wire] - Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced the presentation of results from the DYNAMO® study, a Phase 2 clinical trial evaluating the safety and efficacy of duvelisib in patients with indolent non-Hodgkin lymphoma that is double refractory to both rituximab and chemotherapy, at the American Society of Hematology 2016 Annual Meeting held December 3-6, ...

VERASTEM, INC. Financials

11/15/2016 06:00 pm

Verastem reports 3Q loss

11/7/2016 10:04 pm

Verastem reports 3Q loss

11/7/2016 10:04 pm

Verastem Reports Third Quarter 2016 Financial Results

11/7/2016 09:02 pm

[at noodls] - Company Adds Late-Stage, Complementary Oncology Product Candidate Duvelisib to Pipeline BOSTON--(BUSINESS WIRE)--Nov. 7, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs ...

Verastem Reports Third Quarter 2016 Financial Results

11/7/2016 09:00 pm

[Business Wire] - Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today reported financial results for the third quarter ended September 30, 2016, and also provided an overview of certain corporate developments.

Verastem Announces Presentations at ASH Annual Meeting

11/3/2016 01:01 pm

[Business Wire] - Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced that new data for duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase -delta and PI3K-gamma, will be presented at the American Society of Hematology 2016 Annual Meeting, being held December 3-6, 2016 in San Diego.

Verastem Licenses Duvelisib from Infinity Pharmaceuticals

11/2/2016 11:00 am

[at noodls] - Transaction Adds Complementary Late-Stage Product Candidate from a Clinically Validated Drug Class to Verastem's Pipeline Duvelisib Has Demonstrated Clinical Activity in Lymphoid Malignancies License of ...